Paul Ruddock

Depixus Raises EUR 30.6M (USD 35.4M) in Series A Financing

Retrieved on: 
Wednesday, December 15, 2021
PSIM, RNA, Protein, Genomics, New Senior Investment Group, ENS, Board, PIA, Vichy, Organic acid, USD, Cancer, Genetics, Director, Paul Ruddock, CEO, Biotechnology, EUR, Disease, Nature, Molecule, Nature Research, DNA, Virology, Lansdowne, Liquid biopsy, Gene expression, Genetic variation, Innovation, Partnership, State, Technology, Nature Communications, Vaccine, Medical imaging, 3D printing, Financial services, Bpifrance, EU

This financing brings the company's total equity and grant funding to-date to over EUR 41 million (USD 47 million).

Key Points: 
  • This financing brings the company's total equity and grant funding to-date to over EUR 41 million (USD 47 million).
  • Detection of abnormal changes in base modification patterning have been shown to underpin many disease processes.
  • Moreover, the way in which nucleic acids, especially RNA, are folded and structured is also critical to biological regulation.
  • John Berriman, Chairman of Depixus, said:"Depixus has grown by leaps and bounds since its inception.

Depixus Raises EUR 30.6M (USD 35.4M) in Series A Financing

Retrieved on: 
Wednesday, December 15, 2021
PSIM, RNA, Protein, Genomics, New Senior Investment Group, ENS, Board, PIA, Vichy, Organic acid, USD, Cancer, Genetics, Director, Paul Ruddock, CEO, Biotechnology, EUR, Disease, Nature, Molecule, Nature Research, DNA, Virology, Lansdowne, Liquid biopsy, Gene expression, Genetic variation, Innovation, Partnership, State, Technology, Nature Communications, Renewable energy, Financial services, Vaccine, Medical imaging, 3D printing, Bpifrance, EU

PARIS and CAMBRIDGE, England, Dec. 15, 2021 /PRNewswire/ -- Depixus®, a biotechnology company developing a unique technology for the fast, accurate, and straightforward extraction of multiomic information from DNA, RNA, and proteins, today announces it has raised EUR 30.6 million in an oversubscribed Series A financing. The funds will be used to further develop its proprietary MAGNA™ instrument system, workflows, and reagents towards commercial launch. The round was co-led by Lansdowne Partners and the PSIM Fund operated by Bpifrance on behalf of the French State, with participation by Casdin Capital, and existing investors, including Arix Bioscience. This financing brings the company's total equity and grant funding to-date to over EUR 41 million (USD 47 million).

Key Points: 
  • - The financing will support development of a commercial instrument system based on the company's proprietary and disruptive MAGNA technology.
  • PARIS and CAMBRIDGE, England, Dec. 15, 2021 /PRNewswire/ -- Depixus, a biotechnology company developing a unique technology for the fast, accurate, and straightforward extraction of multiomic information from DNA, RNA, and proteins, today announcesit has raised EUR 30.6 million in an oversubscribed Series A financing.
  • This financing brings the company's total equity and grant funding to-date to over EUR 41 million (USD 47 million).
  • Detection of abnormal changes in base modification patterning have been shown to underpin many disease processes.